DNA vaccine against proliferating endothelial cells and methods of use thereof

Patent 7094410 Issued on August 22, 2006. Estimated Expiration Date:

March 2, 2022. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Patent References

FLK-1 is a receptor for vascular endothelial growth factor
Patent #: 5851999
Issued on: 12/22/1998
Inventor: Ullrich, et al.

DNA vaccination for induction of suppressive T cell response
Patent #: 5939400
Issued on: 08/17/1999
Inventor: Steinman, et al.

Bi-functional plasmid that can act as both a DNA vaccine and a recombinant virus vector Patent #: 6086891
Issued on: 07/11/2000
Inventor: Hurwitz, et al.

Inventors

Application

No. 10090183 filed on 03/02/2002

US Classes:

424/200.1, Recombinant or stably-transformed bacterium encoding one or more heterologous proteins or fragments thereof424/185.1, Amino acid sequence disclosed in whole or in part; or conjugate, complex, or fusion protein or fusion polypeptide including the same424/93.1, WHOLE LIVE MICRO-ORGANISM, CELL, OR VIRUS CONTAINING424/93.2, Genetically modified micro-organism, cell, or virus (e.g., transformed, fused, hybrid, etc.)424/93.4, Bacteria or actinomycetales435/252.3Transformants (e.g., recombinant DNA or vector or foreign or exogenous gene containing, fused bacteria, etc.)

Examiners

Primary: Priebe, Scott D.
Assistant: Burkhart, Michael

Attorney, Agent or Firm

Olson & Hierl, Ltd.

Foreign Patent References

WO 02/03961 WO 01/01/2002

International Classes

A61K 39/00
A61K 48/00
C12N 1/21
A01N 63/00

Abstract

A DNA vaccine effective for inhibiting endothelial cell proliferation comprises a DNA construct operably encoding a vascular endothelial growth factor (VEGF) receptor protein. This invention provides DNA vaccines that encode VEGF receptor-2 (KDR, SEQ ID NO: 2), VEGF receptor-1 (Flt-1, (SEQ ID NO: 4), or Flk-1 (the murine homolog of KDR, SEQ ID NO: 6), DNA sequences SEQ ID NOS: 1, 3, and 5 respectively, as well as methods of using such a DNA vaccine to inhibit vascular endothelial cell proliferation in the tumor micro-environment. Anti-angiogenesis and subsequent decrease in tumor growth and dissemination is achieved.

Other References

Berzofsky, JA et al., “Progress on new vaccine strategies for the immunotherapy and prevention of cancer”, Jun. 2004, J. Clin. Invest. vol. 113: p. 1515-1525.
Restifo, NP et al. “The promise of nucleic acid vaccines”, 2000, Gene Therapy vol. 7: p. 89-92.
Gura, T. “Systems for Identifying New Drugs Are Often Faulty”, Nov. 1997, Science, vol. 278: p. 1041-1042.
Steinman, RM et al., “Immunotherapy: Bewitched, Bothered, and Bewildered No More”, Jul. 2004, Science, vol. 305: p. 197-200.
Ferrara, N. et al. “The biology of VEGF and its receptors”, Jun. 2003, Nat Med., vol. 9: p. 669-676.
Garmory H.S. et al. “Salmonella vaccines for use in humans: present and future perspectives”, Jul. 2002, FEMS Micro. Rev. vol. 26: p. 339-353.
Marshall et al., J. Clin. Oncol. 23(4):720-31 (2005).
Schlom et al., Dev. Biol. (Basel) 116:27-47 (2004).
Shin Sasaki, et al., Nature Biotechnology, vol. 19, pp. 543-547 (Jun. 2001).
Nicholas P Restifo, Nature Biotechnology, vol. 19, pp. 527-528 (Jun. 2001).
Wolfgange W. Leitner, et al., Cancer Research, vol. 60, pp. 51-55 (Jan. 1, 2000).
N.P. Restifo. et al . . . Gene Therapy vol. 7 pp. 89-92 (2000).
Bruce A. Keyt. et al., The Journal of Biological Chemistry, vol. 271, No. 10, pp. 5638-5646 (1996).
Yu-Quan Wei, et al., Nature Medicine, vol. 6, No. 10. pp. 1160-1166 (Oct. 2000).
William Matthews, et al., Proc. Nat'l. Acad. Sci., USA, vol. 88, pp. 9026-9030 (Oct. 1991).
Timothy P. Quinn, et al., Proc. Nat'l. Acad. Sci, USA, vol. 90, pp. 7533-7537 (Aug. 1993).
Rong XIANG, et al., Clinical Cancer Research, vol. 7. pp. 856s-864s (Mar. 2001) (Suppl.).
Andreas G. Niethammer et al Nature Medicine. vol 8 (12). pp 1369-1375 (Dec. 2002).